Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review

Table 3 Prevention of breast events.

Outcome	Studies	Participants	Risk Ratio (M-H, Fixed, 95% CI), I²
Tamoxifen (10 or 20 mg daily) versus no therapy/placebo
Prevention of gynecomastia
• at 3 months	Fradet 2007	94	0.06 (0.01, 0.43), -
• at 6 months	Fradet 2007, Perdona 2005	195	0.10 (0.05, 0.22), 0%
• at 9 to 12 months	Boccardo 2005, Fradet 2007	171	0.17 (0.09, 0.31), 0%
Prevention of breast pain
• at 3 months	Fradet 2007, Saltzstein 2005	165	0.09 (0.03, 0.24), 74%^a
• at 6 months	Fradet 2006, Perdona 2005	195	0.06 (0.02, 0.17), 27%
• at 9 to 12 months	Boccardo 2005, Fradet 2007	171	0.13 (0.06, 0.27), 0%
Tamoxifen (20 mg daily) versus anastrozole (1 mg daily)
Prevention of gynecomastia
• median 12 months	Boccardo 2005	73	0.22 (0.08, 0.58), -
Prevention of breast pain
• median 12 months	Boccardo 2005, Saltzstein 2005	143	0.25 (0.10, 0.64), 0%
Tamoxifen (10 mg daily) versus radiotherapy
Prevention of gynecomastia
• at 6 months	Perdona 2005	100	0.24 (0.09, 0.65), -
Prevention of breast pain
• at 6 months	Perdona 2005	100	0.20 (0.06, 0.65), -

ISSN: 1741-7015